ATE405840T1 - Zusammensetzungen und verfahren zur stabilisierung von transthyretin und zur hemmung von transthyretin-fehlfaltung - Google Patents

Zusammensetzungen und verfahren zur stabilisierung von transthyretin und zur hemmung von transthyretin-fehlfaltung

Info

Publication number
ATE405840T1
ATE405840T1 AT03813782T AT03813782T ATE405840T1 AT E405840 T1 ATE405840 T1 AT E405840T1 AT 03813782 T AT03813782 T AT 03813782T AT 03813782 T AT03813782 T AT 03813782T AT E405840 T1 ATE405840 T1 AT E405840T1
Authority
AT
Austria
Prior art keywords
transthyretin
misfolding
methods
inhibiting
compositions
Prior art date
Application number
AT03813782T
Other languages
English (en)
Inventor
Jeffrey Kelly
Evan T Powers
Hossein Razavi
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32685364&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE405840(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Application granted granted Critical
Publication of ATE405840T1 publication Critical patent/ATE405840T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT03813782T 2002-12-19 2003-12-19 Zusammensetzungen und verfahren zur stabilisierung von transthyretin und zur hemmung von transthyretin-fehlfaltung ATE405840T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43507902P 2002-12-19 2002-12-19
US46543503P 2003-04-24 2003-04-24

Publications (1)

Publication Number Publication Date
ATE405840T1 true ATE405840T1 (de) 2008-09-15

Family

ID=32685364

Family Applications (2)

Application Number Title Priority Date Filing Date
AT03813782T ATE405840T1 (de) 2002-12-19 2003-12-19 Zusammensetzungen und verfahren zur stabilisierung von transthyretin und zur hemmung von transthyretin-fehlfaltung
AT08014241T ATE524741T1 (de) 2002-12-19 2003-12-19 Zusammensetzungen und verwendungen zur stabilisierung von transthyretin und zur hemmung von transthyretin-fehlfaltung

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT08014241T ATE524741T1 (de) 2002-12-19 2003-12-19 Zusammensetzungen und verwendungen zur stabilisierung von transthyretin und zur hemmung von transthyretin-fehlfaltung

Country Status (20)

Country Link
US (6) US7214695B2 (de)
EP (3) EP1988397B8 (de)
JP (3) JP4665076B2 (de)
KR (1) KR101089904B1 (de)
CN (2) CN100448852C (de)
AT (2) ATE405840T1 (de)
AU (2) AU2003303196C1 (de)
BE (1) BE2012C008I2 (de)
BR (1) BRPI0317463B8 (de)
CA (2) CA2510455C (de)
CY (2) CY1108467T1 (de)
DE (2) DE60323155D1 (de)
DK (2) DK1587821T6 (de)
ES (3) ES2312857T7 (de)
FI (1) FI1587821T6 (de)
FR (1) FR12C0008I2 (de)
LU (1) LU91935I2 (de)
PT (2) PT1988397E (de)
SI (1) SI1587821T2 (de)
WO (1) WO2004056315A2 (de)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06105459B2 (ja) * 1988-08-11 1994-12-21 日本電気株式会社 ベクトル処理装置
ES2312857T7 (en) * 2002-12-19 2025-06-13 Scripps Research Inst Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
WO2005089722A1 (en) * 2004-03-12 2005-09-29 Biodel, Inc. Rapid acting drug delivery compositions
WO2005118511A2 (en) 2004-05-20 2005-12-15 The Scripps Research Institute Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
PL1819354T3 (pl) * 2004-08-26 2011-12-30 Biocrine Ab Sposoby i związki do leczenia cukrzycy
US20070037875A1 (en) * 2005-08-11 2007-02-15 The Scripps Research Institute Genistein inhibition of transthyretin amyloidosis
EP2074223A4 (de) * 2006-09-15 2010-03-10 Foldrx Pharmaceuticals Inc Testverfahren zum nachweis von proteinen im nativen zustand und zur identifizierung von die stabilität von proteinen im nativen zustand modulierenden verbindungen
WO2010054127A1 (en) * 2008-11-05 2010-05-14 Elan Pharmaceuticals, Inc. Methods and agents for stabilizing non-pathological amyloidogenic polypeptides
JOP20190231A1 (ar) 2009-01-15 2017-06-16 Incyte Corp طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
CA2751679C (en) 2009-02-06 2018-02-27 Women & Infants' Hospital Of Rhode Island Compositions for treating preeclampsia-type disorders of pregnancy comprising transthyretin
WO2011116123A1 (en) * 2010-03-19 2011-09-22 Irm Llc Tafamidis for the treatment of ophthalmic diseases
CA2796933A1 (en) 2010-04-21 2011-10-27 Chiesi Farmaceutici S.P.A. 1-(2-fluorobiphenyl-4-yl)-alkyl carboxylic acid derivatives for the therapy of transthyretin amyloidosis
WO2011140333A1 (en) 2010-05-07 2011-11-10 The Board Of Trustees Of The Leland Stanford Junior University Identification of stabilizers of multimeric proteins
WO2014037832A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment of epilepsy and neurological diseases
MX2014003043A (es) * 2011-09-16 2015-02-05 Pfizer Formas solidas de un inhibidor de disociacion transtiretina.
CA2873093A1 (en) 2012-05-07 2013-11-14 Cellixbio Private Limited Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
SG11201407300VA (en) 2012-05-07 2014-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of neurological disorders
WO2013167990A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of depression
US9266823B2 (en) 2012-05-08 2016-02-23 Cellix Bio Private Limited Compositions and methods for the treatment of parkinson's disease
US9434704B2 (en) 2012-05-08 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of neurological degenerative disorders
US9403826B2 (en) 2012-05-08 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory disorders
WO2013168025A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of blood clotting disorders
WO2013167991A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic disorders
WO2013168002A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological conditions
WO2013168014A1 (en) * 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of familial amyloid polyneuropathy
US9346742B2 (en) 2012-05-10 2016-05-24 Cellix Bio Private Limited Compositions and methods for the treatment of fibromyalgia pain
WO2013167999A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurologic diseases
US9339484B2 (en) 2012-05-10 2016-05-17 Cellix Bio Private Limited Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
US9573927B2 (en) 2012-05-10 2017-02-21 Cellix Bio Private Limited Compositions and methods for the treatment of severe pain
SG11201407318UA (en) 2012-05-10 2014-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of metabolic syndrome
US9315478B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
WO2013168001A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2013168033A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neurologic diseases
WO2013168011A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of chronic pain
WO2013168015A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of asthma and allergy
US9242939B2 (en) 2012-05-10 2016-01-26 Cellix Bio Private Limited Compositions and methods for the treatment of respiratory disorders
US9227974B2 (en) 2012-05-23 2016-01-05 Cellex Bio Private Limited Compositions and methods for the treatment of respiratory disorders
WO2013175357A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of inflammatory bowel disease
AU2013264896A1 (en) 2012-05-23 2014-11-27 Cellixbio Private Limited Compositions and methods for the treatment of multiple sclerosis
AU2013264820A1 (en) 2012-05-23 2014-11-27 Cellixbio Private Limited Compositions and methods for treatment of mucositis
US9434729B2 (en) 2012-05-23 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
US9492409B2 (en) 2012-05-23 2016-11-15 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2014020480A2 (en) 2012-08-03 2014-02-06 Mahesh Kandula Compositions and methods for the treatment migraine and neurologic diseases
US9624168B2 (en) 2012-09-06 2017-04-18 Cellix Bio Private Limited Compositions and methods for the treatment inflammation and lipid disorders
CA2873029A1 (en) 2012-09-08 2014-03-13 Cellixbio Private Limited Compositions and methods for the treatment of inflammation and lipid disorders
US9169214B2 (en) 2012-12-21 2015-10-27 The Board Of Trustees Of The Leland Stanford Junior University Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions
US9790269B2 (en) 2013-02-08 2017-10-17 Misfolding Diagnostics, Inc. Transthyretin antibodies and uses thereof
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
CA2914461A1 (en) 2013-06-04 2014-12-11 Cellixbio Private Limited Compositions and methods for the treatment of diabetes and pre-diabetes
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
EP3179857B1 (de) 2014-08-14 2021-09-08 Mamoun M. Alhamadsheh Konjugation von pharmazeutischen wirkstoffen mit transthyretinliganden durch anpassbare linker zur erhöhung der serumshalbwertszeit
IL251037B1 (en) 2014-09-08 2024-10-01 Pfizer Crystal structures of 6-carboxy-2-(5,3-dichlorophenyl)-benzoxazole
EP3240779B1 (de) 2014-09-26 2020-10-28 Cellixbio Private Limited Zusammensetzungen und verfahren zur behandlung von epilepsie- und lipidstörungen
CN107207403A (zh) 2014-09-29 2017-09-26 塞尔利克斯生物私人有限公司 用于治疗多发性硬化的组合物和方法
EP3212626B1 (de) 2014-10-27 2018-11-07 Cellix Bio Private Limited Drei-komponenten-salze des fumarsäuremonomethylesters mit piperazin und ethylendiamin zur behandlung von multipler sclerosis
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
CN110845355A (zh) 2015-01-06 2020-02-28 塞尔利克斯生物私人有限公司 用于治疗炎症和疼痛的组合物和方法
CN107344927A (zh) 2016-05-05 2017-11-14 苏州晶云药物科技有限公司 Tafamidis葡甲胺盐的晶型E及其制备方法和用途
CN106496014A (zh) * 2016-10-17 2017-03-15 河北美星化工有限公司 一种二氟尼柳的制备方法
WO2018215831A2 (en) 2017-05-22 2018-11-29 National Hellenic Research Foundation Macrocyclic modulators of disease associated protein misfolding and aggregation
GB2571950A (en) * 2018-03-13 2019-09-18 Azad Pharma Ag New polymorph and new path to synthesize tafamidis
CN108558599B (zh) * 2018-03-29 2021-01-29 浦拉司科技（上海）有限责任公司 2-联苯基甲醇的合成工艺
US12268669B2 (en) 2018-12-20 2025-04-08 Pfizer Inc. Pharmaceutical compositions and methods comprising a combination of a benzoxazole transthyretin stabilizer and an additional therapeutic agent
PL3953339T3 (pl) * 2019-04-11 2025-05-05 Inke, S.A. Proces otrzymania 1-deoksy-1-metyloamino-d-glucitolu 2-(3,5-dichlorofenylo)-6-benzoksazolokarboksylanu
HRP20250159T1 (hr) 2019-05-16 2025-03-28 Assia Chemical Industries Ltd. Kruti oblici tafamidisa i njegovih soli
CN110215740B (zh) * 2019-07-15 2021-05-04 大连医科大学 一种两性离子亲水前处理硅胶材料的制备方法
WO2021019448A1 (en) * 2019-08-01 2021-02-04 Honour (R&D) Process for the preparation of transthyretin dissociation inhibitor
WO2021093809A1 (zh) 2019-11-15 2021-05-20 苏州科睿思制药有限公司 他发米帝司的晶型及其制备方法和用途
CA3165298A1 (en) * 2019-12-20 2021-06-24 Pfizer Ireland Pharmaceuticals Efficient process for making 6-carboxy benzoxazole derivatives
WO2021152623A1 (en) * 2020-01-27 2021-08-05 Dr. Reddy’S Laboratories Limited Improved processes for the preparation of tafamidis and its meglumine salt
WO2021154842A1 (en) 2020-01-28 2021-08-05 Protego Biopharma, Inc. Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
WO2022112919A1 (en) 2020-11-25 2022-06-02 Pfizer Inc. (aza)benzothiazolyl substituted pyrazole compounds
CN112683844A (zh) * 2020-12-07 2021-04-20 东华理工大学 一种振动对吲哚美辛-糖精共晶形成影响的研究方法
CN112858690B (zh) * 2021-01-21 2023-11-10 宁波职业技术学院 一种尿白蛋白/尿肌酐复合质控品及其制备方法
CN114907283B (zh) * 2021-02-07 2025-01-28 南京正大天晴制药有限公司 一种2-(3，5-二氯苯基)-苯并噁唑-6-羧酸的制备方法
EP4083027A1 (de) 2021-04-26 2022-11-02 Química Sintética, S.A. Festkörperform von tafamidis und verfahren zu deren herstellung
CN113372290A (zh) * 2021-05-21 2021-09-10 遵义医科大学 一种药物Tafamidis的合成方法
CN113321627B (zh) * 2021-06-06 2022-05-24 湖南第一师范学院 一种Tafamidis衍生物及其合成方法
WO2022260939A2 (en) 2021-06-08 2022-12-15 Alnylam Pharmaceuticals, Inc. Compositions and methods for treating or preventing stargardt's disease and/or retinal binding protein 4 (rbp4)-associated disorders
WO2023020762A1 (en) 2021-08-16 2023-02-23 Synthon B.V. Crystalline forms of tafamidis nicotinamide adduct
WO2023091534A1 (en) 2021-11-17 2023-05-25 Teva Pharmaceuticals International Gmbh Solid state form of tafamidis
CN114970600B (zh) * 2022-04-11 2024-07-26 昆明理工大学 基于粒化散布熵和优化kelm的滚动轴承故障诊断方法、装置
WO2024019180A1 (ja) 2022-07-22 2024-01-25 白鳥製薬株式会社 タファミジス又はその塩の製造方法
JP2025524085A (ja) 2022-07-28 2025-07-25 ファイザー・インク タファミジス医薬組成物
US11970468B1 (en) 2023-10-23 2024-04-30 King Faisal University 2-(benzo[d]oxazol-2-yl)-N′-(3,5-dichlorobenzoyloxy)acetimidamide as an antimicrobial compound

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US435079A (en) 1890-08-26 Lock-nut for axles
DE602336C (de) 1933-03-09 1934-09-06 I G Farbenindustrie Akt Ges Verfahren zur Herstellung von Kuepenfarbstoffen der Anthrachinonreihe
US3551433A (en) * 1967-06-21 1970-12-29 Us Army Preparation of 4-phenyl-4-acyloxypiperidine
US3551443A (en) 1968-10-30 1970-12-29 Ciba Ltd 2-phenylbenzoxazole derivatives
USRE29608E (en) * 1972-05-18 1978-04-11 Lilly Industries Limited Benzoxazole derivatives
DE2314238A1 (de) 1973-03-22 1974-09-26 Henkel & Cie Gmbh Neue 2-(tetrazol-5'-yl)-benzoxazole, deren herstellung sowie verwendung als entzuendungshemmer in kosmetischen praeparationen
US4025637A (en) * 1973-10-23 1977-05-24 Lilly Industries, Ltd. 2,5 OR 2,6 Disubstituted benzoxazoles
US4025636A (en) * 1973-10-23 1977-05-24 Lilly Industries, Ltd. 2-(Optionally substituted)phenyl-5 or 6-substituted benzoxazoles
DE2619547A1 (de) * 1976-05-04 1977-11-24 Dynamit Nobel Ag Verfahren zur herstellung von 2-aryl- benzoxazolen und 2-aryl-benzthiazolen
US4416892A (en) 1981-04-23 1983-11-22 Lilly Industries Limited Method of treating hypersensitivity disease with benzoxazole derivatives
US5254692A (en) 1990-04-06 1993-10-19 Bayer Aktiengesellschaft 2,6-dialkyl-4-(benzothiazol- or benzoxazol-7-yl)-1,4-dihydropyridines
DE4011106A1 (de) * 1990-04-06 1991-10-10 Bayer Ag Neue heterocyclisch substituierte dihydropyridine, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
US5037842A (en) * 1990-06-05 1991-08-06 Pfizer Inc. Oxa- and thiazolidinedione hypoglycemic and hypocholesterolemic agents
CA2051518A1 (en) 1990-10-01 1992-04-02 Robert J. Perry Synthesis of heterocyclic compounds
JP3021028B2 (ja) 1990-11-19 2000-03-15 株式会社日本化学工業所 アゾール型カチオン染料
CH681806A5 (de) 1991-03-19 1993-05-28 Ciba Geigy Ag
JPH0517458A (ja) 1991-07-04 1993-01-26 Idemitsu Kosan Co Ltd 芳香族化合物とその製造方法
US5354759A (en) 1991-09-12 1994-10-11 Fujisawa Pharmaceutical Co., Ltd. Angiotenin II antagonizing heterocyclic compounds
JPH0673050A (ja) 1992-08-26 1994-03-15 Asahi Glass Co Ltd ヘテロ環化合物
JPH0673051A (ja) 1992-08-26 1994-03-15 Asahi Glass Co Ltd ベンズアゾール誘導体
GB9218334D0 (en) 1992-08-28 1992-10-14 Ici Plc Heterocyclic compounds
JPH06239849A (ja) 1993-02-16 1994-08-30 Canon Inc 光学活性化合物、これを含む液晶組成物、それを有する液晶素子、それらを用いた表示方法及び表示装置
DE4304650A1 (de) 1993-02-16 1994-08-18 Thomae Gmbh Dr K Kondensierte 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
JP3243887B2 (ja) 1993-05-28 2002-01-07 三菱化学株式会社 有機電界発光素子
JPH0797379A (ja) 1993-09-06 1995-04-11 Canon Inc 液晶性化合物、これを含む液晶組成物、それを有する液晶素子、それらを用いた表示方法および表示装置
US5441946A (en) 1994-04-14 1995-08-15 Rhone-Poulenc-Rorer Pharmaceuticals, Inc. Phosphonate derivatives of lipophilic amines
US5552426A (en) 1994-04-29 1996-09-03 Eli Lilly And Company Methods for treating a physiological disorder associated with β-amyloid peptide
US5837390A (en) 1995-05-10 1998-11-17 Sony Corporation Metal complex, method for producing the same and optical device
JP3861930B2 (ja) 1995-12-15 2006-12-27 ソニー株式会社 金属複核錯体、その製造方法及び光学的素子
JPH09227576A (ja) 1996-02-23 1997-09-02 Sony Corp 金属複核錯体、その製造方法及び光学的素子
JP3760508B2 (ja) 1996-06-10 2006-03-29 東洋インキ製造株式会社 有機エレクトロルミネッセンス素子材料およびそれを用いた有機エレクトロルミネッセンス素子
WO1997047319A1 (en) 1996-06-14 1997-12-18 Progenics Pharmaceuticals, Inc. Uses of a chemokine receptor for inhibiting hiv-1 infection
WO1998027972A2 (en) 1996-12-23 1998-07-02 Texas A & M University Anti-amyloidogenic agents
FR2767527B1 (fr) 1997-08-25 1999-11-12 Pf Medicament Derives de piperazines indoliques, utiles comme medicaments et procede de preparation
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
AU2494799A (en) 1998-02-04 1999-08-23 Board Of Regents, The University Of Texas System Inhibition of human telomerase by a g-quadruplex-interaction compound
US6107491A (en) 1998-07-20 2000-08-22 Ciba Specialty Chemicals Corporation Polymerizable diketopyrrolopyrroles
GB9816654D0 (en) 1998-07-30 1998-09-30 Zeneca Ltd Chemical compounds
JP2000100569A (ja) 1998-09-22 2000-04-07 Toray Ind Inc 発光素子
JP2001055332A (ja) 1999-06-07 2001-02-27 Saitama Daiichi Seiyaku Kk 芳香族アミジン誘導体類含有のイオントフォレ−シス用製剤
JP2003502408A (ja) 1999-06-18 2003-01-21 バイエル アクチェンゲゼルシャフト フェノキシフルオロピリミジン類
JP2001064205A (ja) 1999-06-25 2001-03-13 Dai Ichi Seiyaku Co Ltd 製剤組成物
JP2001064166A (ja) 1999-06-25 2001-03-13 Dai Ichi Seiyaku Co Ltd 貼付剤
US6420418B1 (en) 1999-08-16 2002-07-16 Merck & Co., Inc. Heterocycle amides as cell adhesion inhibitors
GB9919673D0 (en) 1999-08-20 1999-10-20 Cancer Res Campaign Tech 2-Arlybenzazole compounds
JP2001226358A (ja) 1999-10-12 2001-08-21 Japan Tobacco Inc Ｌｐｌ活性増強剤
JP2001242165A (ja) 2000-02-25 2001-09-07 Dai Ichi Seiyaku Co Ltd 採血用試薬
EP1265853A1 (de) 2000-03-16 2002-12-18 F. Hoffmann-La Roche AG Carbonsäure-derivate als ip-antagonisten
GB0007934D0 (en) 2000-03-31 2000-05-17 Darwin Discovery Ltd Chemical compounds
JP3945123B2 (ja) 2000-04-10 2007-07-18 三菱化学株式会社 有機電界発光素子
JP2001301329A (ja) 2000-04-20 2001-10-31 Mitsubishi Chemicals Corp 光学記録媒体
JP2002003368A (ja) 2000-06-23 2002-01-09 Saitama Daiichi Seiyaku Kk 経皮吸収又は経粘膜吸収用の製剤
BRPI0113470B8 (pt) 2000-08-24 2021-05-25 Univ Pittsburgh composto de ligação amilóide, composição farmacêutica e métodos de síntese de composto, de detecção in vivo de depósitos amilóides num indivíduo e em tecido humano ou animal, de quantificação de depósito amilóide em tecido de biópsia ou postmortem e de distinção de um cérebro de doença de alzheimer de um cérebro normal
WO2002036553A2 (en) 2000-11-04 2002-05-10 Aventis Pharma Limited Substituted alkanoic acids
US20070004713A1 (en) 2000-12-07 2007-01-04 Bernard Barlaam Therapeutic benimidazole compounds
WO2002051821A1 (en) 2000-12-22 2002-07-04 Astrazeneca Ab Therapeutic compounds
GB0118357D0 (en) 2001-07-27 2001-09-19 Syngenta Ltd Chemical compounds
AU2002334355A1 (en) 2001-09-06 2003-03-18 Prochon Biotech Ltd. Protein tyrosine kinase inhibitors
US6602619B2 (en) 2001-10-19 2003-08-05 Lightronik Technology Inc. Organic EL device
KR100919147B1 (ko) 2001-11-16 2009-09-25 닛뽕 케미파 가부시키가이샤 크산틴 옥시다제 저해제
WO2003045930A1 (en) 2001-11-28 2003-06-05 Astrazeneca Ab Therapeutic compounds
UA83620C2 (ru) 2001-12-05 2008-08-11 Уайт Замещенные бензоксазолы и их аналоги как эстрогенные агенты
BR0215240A (pt) 2001-12-19 2004-10-26 Atherogenics Inc Derivados de calcona e seu uso no tratamento de doenças
US7202247B2 (en) 2001-12-19 2007-04-10 Atherogenics, Inc. 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
GB0205256D0 (en) 2002-03-06 2002-04-17 Oxford Glycosciences Uk Ltd Novel compounds
JP2005520858A (ja) 2002-03-20 2005-07-14 メタボレックス， インコーポレイテッド 置換フェニル酢酸
UA79755C2 (en) 2002-04-16 2007-07-25 Bayer Pharmaceuticals Corp Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
GB0226822D0 (en) 2002-11-16 2002-12-24 Oxford Glycosciences Uk Ltd Novel compounds
ES2312857T7 (en) 2002-12-19 2025-06-13 Scripps Research Inst Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
US7332516B2 (en) 2003-01-14 2008-02-19 Merck + Co., Inc. Geminally di-substituted NSAID derivatives as Aβ42 lowering agents
JP2004250411A (ja) 2003-02-21 2004-09-09 Bf Kenkyusho:Kk アミロイドβ蓄積性疾患の診断プローブおよび治療用化合物
CA2438032C (en) 2003-03-14 2013-05-07 University Of Pittsburgh Benzothiazole derivative compounds, compositions and uses
AR044503A1 (es) 2003-03-18 2005-09-14 Merck & Co Inc Triazoles sustituidos con biarilo como bloqueantes del canal de sodio
EP1608622A4 (de) 2003-03-24 2009-04-01 Merck & Co Inc Biarylsubstituierte 6-gliedrige heterocyclen als natriumkanalblocker
JP2004302049A (ja) 2003-03-31 2004-10-28 Hodogaya Chem Co Ltd 感光性樹脂組成物
CN101333192A (zh) 2003-04-03 2008-12-31 默克公司 作为钠通道阻滞剂的联芳基取代吡唑
AU2004232936B2 (en) 2003-04-18 2008-10-30 Merck & Co., Inc. Biaryl substituted thiazoles, oxazoles and imidazoles as sodium channel blockers
WO2004098494A2 (en) 2003-04-30 2004-11-18 Cytokinetics, Inc. Compounds, compositions, and methods
WO2005118511A2 (en) * 2004-05-20 2005-12-15 The Scripps Research Institute Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding

Also Published As

Publication number Publication date
FR12C0008I2 (fr) 2013-01-11
CA2510455A1 (en) 2004-07-08
DE122012000007I1 (de) 2012-04-12
EP1587821A4 (de) 2007-05-09
CY1108467T1 (el) 2014-04-09
DK1587821T6 (da) 2025-05-26
AU2010201263B8 (en) 2013-04-18
DK1988397T3 (da) 2011-12-12
LU91935I9 (de) 2019-01-04
CA2510455C (en) 2013-03-12
JP4665076B2 (ja) 2011-04-06
DE60323155D1 (de) 2008-10-02
ATE524741T1 (de) 2011-09-15
CN101413143B (zh) 2013-09-18
EP1988397B8 (de) 2012-02-15
WO2004056315A2 (en) 2004-07-08
AU2003303196C1 (en) 2021-03-25
CY2012005I2 (el) 2015-10-07
EP2325651B1 (de) 2014-10-08
FI1587821T9 (fi) 2025-07-30
AU2003303196B2 (en) 2010-03-25
US20140134753A1 (en) 2014-05-15
EP2325651A2 (de) 2011-05-25
US20070078186A1 (en) 2007-04-05
WO2004056315A3 (en) 2005-08-11
KR101089904B1 (ko) 2011-12-05
AU2003303196A1 (en) 2004-07-14
US20060057644A1 (en) 2006-03-16
EP1988397A1 (de) 2008-11-05
CA2800237A1 (en) 2004-07-08
CA2800237C (en) 2016-05-17
DK1587821T3 (da) 2008-11-10
ES2373639T3 (es) 2012-02-07
BR0317463A (pt) 2005-11-16
EP1587821B9 (de) 2025-07-02
EP1587821B1 (de) 2008-08-20
CN101413143A (zh) 2009-04-22
JP2006511612A (ja) 2006-04-06
BRPI0317463B8 (pt) 2021-05-25
US20100120919A1 (en) 2010-05-13
US8168663B2 (en) 2012-05-01
AU2010201263A8 (en) 2013-04-18
ES2524803T3 (es) 2014-12-12
CY2012005I1 (el) 2015-10-07
AU2010201263A1 (en) 2010-04-22
SI1587821T1 (sl) 2009-02-28
EP1587821A2 (de) 2005-10-26
EP1587821B3 (de) 2025-04-30
JP2013256521A (ja) 2013-12-26
US7214695B2 (en) 2007-05-08
US20120065237A1 (en) 2012-03-15
SI1587821T2 (sl) 2025-06-30
ES2312857T3 (es) 2009-03-01
JP5756151B2 (ja) 2015-07-29
AU2010201263B2 (en) 2012-12-20
PT1587821E (pt) 2008-09-23
US7560488B2 (en) 2009-07-14
EP2325651A3 (de) 2011-09-21
BE2012C008I2 (de) 2023-03-07
CN1747965A (zh) 2006-03-15
ES2312857T7 (en) 2025-06-13
EP1988397B1 (de) 2011-09-14
LU91935I2 (fr) 2012-03-26
US8653119B2 (en) 2014-02-18
US7214696B2 (en) 2007-05-08
KR20050090410A (ko) 2005-09-13
CN100448852C (zh) 2009-01-07
WO2004056315A8 (en) 2005-12-08
US20040152140A1 (en) 2004-08-05
PT1988397E (pt) 2011-12-02
FR12C0008I1 (de) 2012-03-30
FI1587821T6 (fi) 2025-06-17
BRPI0317463B1 (pt) 2017-04-18
JP2010270134A (ja) 2010-12-02

Similar Documents

Publication Publication Date Title
ATE405840T1 (de) Zusammensetzungen und verfahren zur stabilisierung von transthyretin und zur hemmung von transthyretin-fehlfaltung
DE60219917D1 (de) Naphtoquinone derivate als inhibitoren von tau aggregation zur behandlung von alzheimer's und verbundenen neurodegenerativen erkrankungen
DE602004018338D1 (de) Prävention und behandlung von durch entzündung ausgelöstem und/oder immunvermitteltem knochenschwund
EA200900802A1 (ru) Способы и композиции для лечения амилоидных заболеваний
EA200600078A1 (ru) Способы и композиции для лечения амилоидных заболеваний
EA200601555A1 (ru) Замещенные индазол-о-глюкозиды
EA200601554A1 (ru) Замещенные индол-о-глюкозиды
ATE432072T1 (de) Verwendung von adapalen zur behandlung dermatologischer erkrankungen
DE60330161D1 (de) Rifalazil zur behandlung von infektionen mit clostridium difficile
ATE492542T1 (de) Herstellung und anwendung von biphenyl-4-yl- carbonylaminosäurederivaten zur behandlung von obesitas
EA200500856A1 (ru) Новые химические соединения
ATE428413T1 (de) Neue verwendung von peptidverbindungen zur behandlung ovn zentralen neuropathischen schmerzen
ATE336996T1 (de) Verwendung von flavonoid-derivaten zur behandlung von atopischem ekzem
ATE318606T1 (de) Zusammenstellungen zur prophylaxe und behandlung von allergien des typus i
ATE362362T1 (de) Zusammensetzung von einem ppar-alpha agonisten und metformin zur behandlung von obesitas
ATE469657T1 (de) Immunstimulatorische kombination zur vorbeugung und behandlung von hepatitis c
DE60213365D1 (de) Verwendung von mglur5 antagonisten zur behandlung von pruritischen zuständen
DE602006015971D1 (de) Zusammensetzung zur behandlung von uveitis
ATE533495T1 (de) Zusammensetzungen zur behandlung von hautkrankheiten gekennzeichnet durch exsudation von serumproteinen
DE60200713D1 (de) Zusammensetzung enthaltend getrocknetes Vollei zur Behandlung von Hepatitis
ATE482217T1 (de) Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen
DE60219495D1 (de) Verwendung von Interleukin-18 zur Behandlung von UV-assoziierten Hautkrankheiten
ATE429250T1 (de) Mittel zur behandlung der allergischen kontaktdermatitis
DE60215947D1 (de) Pyridin-2-yl-methylamin-derivate zur behandlung von opiatsucht